A Phase 2/3 Open-label Study to Evaluate the Safety, Tolerability, Efficacy and PK of Remdesivir in Participants from Birth to < 18 years of age with COVID-19
To evaluate the safety and tolerability of RDV in participants withlaboratory confirmed COVID-19 aged 28 days to < 18 years. To evaluate the safety and tolerability of RDV in participants with laboratory confirmed COVID-19 aged 0 days to < 28 days